Genomind is a personalized medicine company that helps clinicians optimize treatment decisions for their patients with mental illness. The company's flagship product, the Genecept Assay, is a genetic test that informs mental health treatment decisions by identifying patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect, or cause adverse effects. The Genecept Assay is used by thousands of clinicians across the United States and has been shown to improve patient outcomes and reduce healthcare costs. Genomind was founded in 2009 and is headquartered in King of Prussia, Pennsylvania.